Sanofi (SNYNF,SNY) and Novavax Inc. (NVAX) announced a co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop Novel COVID-19-Influenza combination vaccines. In addition, Sanofi will take a minority equity stake below 5% in Novavax.
The agreement encompasses several key terms: a co-exclusive license for global co-commercialization of Novavax's current standalone adjuvanted COVID-19 vaccine, with exceptions for countries covered by existing Advance Purchase Agreements and in India, Japan, and South Korea due to preexisting partnership agreements; a sole license to employ Novavax's adjuvanted COVID-19 vaccine alongside Sanofi's flu vaccines, while Novavax maintains the rights to develop its own COVID-19-Influenza Combination vaccine; a non-exclusive license for utilizing Novavax's adjuvanted COVID-19 vaccine in combination with non-flu vaccines; and a non-exclusive license for incorporating the Matrix-M adjuvant in vaccine products.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.